
    
      This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are
      planned (5 groups of 6 subjects each) as follows:

      Group A: Subjects with ESRD who are receiving hemodialysis treatment

      Group B: Subjects with severe renal impairment

      Group C: Subjects with moderate renal impairment

      Group D: Subjects with mild renal impairment

      Group E: Healthy subjects
    
  